TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28624664

Group type: EXPERIMENTAL
Intervention: Full-thickness excision of bladder endometriosis nodule (70%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Excision of bladder wall without opening of bladder (30%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ureterolysis (78%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Primary segmental resection (22%)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Surgical management of urinary tract endometriosis
Number of subjects: 81
Study: 28624860

Group type: EXPERIMENTAL
Intervention: Normal weight group (BMI < 25)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Obese group (BMI > 30)
Number of subjects: 46
Study: 28625365

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28625380

Group type: EXPERIMENTAL
Intervention: NOACs (including dabigatran, rivaroxaban, apixaban)
Number of subjects: 4670

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4670
Study: 28625502

Group type: EXPERIMENTAL
Intervention: Computable phenotype
Number of subjects: 413

Group type: COMPARATOR
Intervention: Registry
Number of subjects: 413
Study: 28625503

Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE) 10 mg/day
Number of subjects: 8
Study: 28625579

Group type: EXPERIMENTAL
Intervention: Monocyte Distribution Width (MDW)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: MDW + WBC count
Number of subjects: 1320
Study: 28625629

Group type: EXPERIMENTAL
Intervention: Afatinib 30mg and sirolimus 1mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Afatinib and sirolimus
Number of subjects: 39
Study: 28625777

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (Herceptin) 600 mg fixed-dose every 3 weeks for 18 cycles
Number of subjects: 2573
Study: 28625816

Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 22
Study: 28625834

Group type: EXPERIMENTAL
Intervention: NK cell activity test
Number of subjects: 872
Study: 28625964

Group type: EXPERIMENTAL
Intervention: Antegrade dissection and reentry (ADR)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Controlled ADR (combined CrossBoss-Stingray)
Number of subjects: 292
Study: 28626781

Group type: EXPERIMENTAL
Intervention: Cladribine (3.5 mg/kg; 5.25 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine (3.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 0
Study: 28629333

Group type: EXPERIMENTAL
Intervention: 4.5-month fluoroquinolone-containing regimen (levofloxacin, isoniazid, rifampin, parazinamid, ethambutol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4.5-month regimen (isoniazid, rifampin, parazinamid, ethambutol without levofloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (2 months of isoniazid, rifampin, parazinamid, ethambutol followed by 4 months of isoniazid and rifampin)
Number of subjects: 0
Study: 28629348

Group type: EXPERIMENTAL
Intervention: Direct-mail fecal immunochemical testing (FIT) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDSA process
Number of subjects: 0
Study: 28629390

Group type: EXPERIMENTAL
Intervention: REX powered walking aid
Number of subjects: 20
Study: 28629395

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) therapy initiated based on EASL criteria; 74 patients (24.7%) started TDF therapy, 46 (62.2%) had cirrhosis.
Number of subjects: 300
Study: 28629437

Group type: EXPERIMENTAL
Intervention: AutoSyp programmed to deliver magnesium sulfate (MgSO4) intravenously
Number of subjects: 22
Study: 28629466

Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction (SVF) and platelet rich plasma (PRP) intra-articular injection
Number of subjects: 10
Study: 28629584

Group type: EXPERIMENTAL
Intervention: Met the vitamin D estimated average requirement (EAR) intake (10 μg/d)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sufficient serum 25-hydroxyvitamin D (25(OH)D) (≥50 nmol/L)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Did not meet the vitamin D EAR
Number of subjects: 132

Group type: COMPARATOR
Intervention: Serum levels at risk for inadequacy or deficiency (<50 nmol/L)
Number of subjects: 132
Study: 28630037

Group type: EXPERIMENTAL
Intervention: bant app plus usual care
Number of subjects: 92

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 92
Study: 28630120

Group type: EXPERIMENTAL
Intervention: Selinexor
Number of subjects: 0

Group type: COMPARATOR
Intervention: TPO agonists
Number of subjects: 0
Study: 28630121

Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO) therapy
Number of subjects: 0
Study: 28630189

Group type: EXPERIMENTAL
Intervention: Delafloxacin
Number of subjects: 0
Study: 28630212

Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT) combined with Cytoreductive Nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28630876

Group type: EXPERIMENTAL
Intervention: SIB-IMRT with doses of 69Gy, 75Gy, and 81Gy in 30 fractions to the internal gross tumor volume (iGTV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard IMRT plans prescribed a dose of 60Gy to the planning tumor volume (PTV)
Number of subjects: 20
Study: 28631088

Group type: EXPERIMENTAL
Intervention: ARDS patients with no identified risk factors
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Open lung biopsy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Left heart filling pressures assessment
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Specific diagnosis made
Number of subjects: 234
Study: 28631283

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) and having both parents living together
Number of subjects: 417
Study: 28632462

Group type: EXPERIMENTAL
Intervention: Group Integrated Cognitive-Behavioral Therapy (ICBT)
Number of subjects: 123
Study: 28633365

Group type: EXPERIMENTAL
Intervention: Copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Copanlisib
Number of subjects: 84
Study: 28633375

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with a self-expanding bioprosthesis
Number of subjects: 1015
Study: 28633425

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 97
Study: 28633478

Group type: EXPERIMENTAL
Intervention: 3D transoesophageal echocardiography-derived formula for device size determination without balloon sizing
Number of subjects: 248

Group type: COMPARATOR
Intervention: 3D transoesophageal echocardiography-derived formula for device size determination with balloon sizing
Number of subjects: 248
Study: 28634491

Group type: EXPERIMENTAL
Intervention: Daily growth hormone treatment (group A, 16 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Three-times-weekly growth hormone treatment (group B, 16 patients)
Number of subjects: 32
Study: 28636901

Group type: EXPERIMENTAL
Intervention: CD34
Number of subjects: 0
Study: 28637445

Group type: EXPERIMENTAL
Intervention: Standard local practice treatment for posterior fossa tumours
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standardized surgical data
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Other therapeutic interventions
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Host genome variants
Number of subjects: 500
Study: 28637514

Group type: EXPERIMENTAL
Intervention: POC-INR measurement using Coagucheck® XS Pro device
Number of subjects: 98

Group type: COMPARATOR
Intervention: lab-INR measurement on plasma
Number of subjects: 98
Study: 28637631

Group type: EXPERIMENTAL
Intervention: Remote Food Photography Method (RFPM)
Number of subjects: 54
Study: 28637662

Group type: EXPERIMENTAL
Intervention: Daratumumab plus pomalidomide and dexamethasone (pom-dex)
Number of subjects: 103
Study: 28637738

Group type: EXPERIMENTAL
Intervention: Immune monitoring and immune-stimulating therapies
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Whole-blood TNF-α production tests
Number of subjects: 550
Study: 28637772

Group type: EXPERIMENTAL
Intervention: Increased supplemented dietary intakes of methionine
Number of subjects: 0
Study: 28637923

Group type: EXPERIMENTAL
Intervention: Malaria sporozoites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled human malaria infection (CHMI)
Number of subjects: 0
Study: 28638328

Group type: EXPERIMENTAL
Intervention: General anesthesia with intravenous infusion of propofol and maintenance with isoflurane for 3 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Awake controls
Number of subjects: 60
Study: 28639987

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs)
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Heparin therapy
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapies
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin, GPIs, bivalirudin
Number of subjects: 2585
Study: 28640364

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily)
Number of subjects: 50
Study: 28641783

Group type: EXPERIMENTAL
Intervention: Offspring of T1D women (index offspring)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control offspring
Number of subjects: 568
Study: 28642288

Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 31
Study: 28642315

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide, dosage and duration not available
Number of subjects: 0
Study: 28642620

Group type: EXPERIMENTAL
Intervention: Pomalidomide (1-4 mg days 1-14), bortezomib (1-1.3 mg/m2), low-dose dexamethasone (LoDEX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib (subcutaneous (SC) or intravenous (IV))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (LoDEX)
Number of subjects: 0
Study: 28642820

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory allogeneic dendritic cells (DCs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard tyrosine kinase inhibitors (TKI)
Number of subjects: 12
Study: 28642891

Group type: EXPERIMENTAL
Intervention: VX15/2503 (1, 3, 6, 10, or 20 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VX15/2503
Number of subjects: 50
Study: 28643171

Group type: EXPERIMENTAL
Intervention: Contact-force (CF) sensing technology with radiofrequency energy ablation, targeting at least 10g (ideally 20g) of force, with the endpoint of eliminating the negative component of the unipolar atrial signal.
Number of subjects: 215
Study: 28643214

Group type: EXPERIMENTAL
Intervention: Boston Lotus Valve
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Edwards Sapien S3
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Edwards Sapien XT
Number of subjects: 400

Group type: COMPARATOR
Intervention: Medtronic CoreValve
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: New generation devices (Boston Lotus and Edwards Sapien 3)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Last generation devices (Medtronic CoreValve and Edwards Sapien XT)
Number of subjects: 400
Study: 28643275

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of nitisinone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Twice-daily dosing of nitisinone
Number of subjects: 19
Study: 28644056

Group type: EXPERIMENTAL
Intervention: Nanoparticles (NANOM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ferro
Number of subjects: 180

Group type: COMPARATOR
Intervention: Stenting (XIENCE V)
Number of subjects: 180
Study: 28644099

Group type: EXPERIMENTAL
Intervention: Continuous irrigation and drainage (CID)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Passive subdural drainage (PD)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Active subgaleal drainage (AD)
Number of subjects: 1260
Study: 28644367

Group type: EXPERIMENTAL
Intervention: Cholic acid (10 to 15 mg·kg·day)
Number of subjects: 85
Study: 28644602

Group type: EXPERIMENTAL
Intervention: Total laparoscopic repair
Number of subjects: 228

Group type: COMPARATOR
Intervention: Conventional open aortic surgery
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Laparoscopic aortic surgery
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 228
Study: 28645324

Group type: EXPERIMENTAL
Intervention: Physical Activity Guidelines (PAGs) compliance
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA) measured with SenseWear™ armband
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Vigorous Physical Activity recommendation
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Sedentary time reduction recommendation
Number of subjects: 419
Study: 28645776

Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily) at various doses (20 mg, 40 mg, 80 mg, 120 mg, 200 mg, 300 mg, or 450 mg)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily) at various doses
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Gilteritinib (oral, once daily)
Number of subjects: 252
Study: 28645867

Group type: COMPARATOR
Intervention: Pressure pain tolerance
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pain ratings to repetitive suprathreshold electrical stimulation (SES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Event-related potentials (ERPs) in response to repetitive SES
Number of subjects: 18
Study: 28645891

Group type: EXPERIMENTAL
Intervention: Health apps (various types including exercise, fitness, diet, and mental health apps)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Health apps (various types)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Mental health apps
Number of subjects: 176
Study: 28645937

Group type: EXPERIMENTAL
Intervention: Guideline-recommended treatments for ST-elevation myocardial infarction
Number of subjects: 12108

Group type: EXPERIMENTAL
Intervention: Defect-free rate of guideline-recommended treatments
Number of subjects: 12108

Group type: EXPERIMENTAL
Intervention: Risk-standardized mortality rates
Number of subjects: 12108
Study: 28645967

Group type: EXPERIMENTAL
Intervention: Composite blood-based biomarker
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Composite electronic smartphone-based biomarker
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Neurocognitive and neuroimaging-based signature
Number of subjects: 600
Study: 28646344

Group type: EXPERIMENTAL
Intervention: Chemotherapy A+B (after biomarker information)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Chemotherapy A alone (without biomarker information)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Physician recommendations (after biomarker information)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Physician recommendations (without biomarker information)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Switch in treatment preference (after biomarker information)
Number of subjects: 439
Study: 28646851

Group type: EXPERIMENTAL
Intervention: Educational campaign to increase stroke awareness and preparedness, targeting family settings and using a narrative approach in cartoon form.
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Educational campaign materials tested in focus groups for suitability.
Number of subjects: 595
Study: 28647166

Group type: EXPERIMENTAL
Intervention: V920 (recombinant vesicular stomatitis virus vaccine)
Number of subjects: 17000
Study: 28647272

Group type: EXPERIMENTAL
Intervention: Withdrawal or withholding of life-sustaining therapy (WWLST) discussions
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Intensive care continued
Number of subjects: 3434

Group type: COMPARATOR
Intervention: WWLST discussions
Number of subjects: 3434
Study: 28647444

Group type: EXPERIMENTAL
Intervention: Spot urine protein-to-creatinine ratio (PCR)
Number of subjects: 205
Study: 28647669

Group type: EXPERIMENTAL
Intervention: Engage therapy (9 weekly sessions)
Number of subjects: 48
Study: 28648122

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45-mg oral dose
Number of subjects: 14
Study: 28648475

Group type: EXPERIMENTAL
Intervention: DHA supplementation for 48 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 84
Study: 28649383

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 89
Study: 28649417

Group type: EXPERIMENTAL
Intervention: Puff City (Web-based asthma management program)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Generic Web-based program (control)
Number of subjects: 121
Study: 28649553

Group type: EXPERIMENTAL
Intervention: MPS II patients with cognitive impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPS II patients with the attenuated phenotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 28649644

Group type: EXPERIMENTAL
Intervention: Constitutional variants (single nucleotide polymorphisms)
Number of subjects: 9836

Group type: EXPERIMENTAL
Intervention: Genome-Wide Association Study
Number of subjects: 9836
Study: 28649807

Group type: EXPERIMENTAL
Intervention: miR196a2, miR196a1, miR196b, and miR204
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: miR196
Number of subjects: 18
Study: 28651158

Group type: EXPERIMENTAL
Intervention: High lymphocyte infiltration (LI)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Low lymphocyte infiltration (LI)
Number of subjects: 1220
Study: 28651258

Group type: EXPERIMENTAL
Intervention: Foley Balloon Induction of Labor
Number of subjects: 0
Study: 28651336

Group type: EXPERIMENTAL
Intervention: Lotus Valve
Number of subjects: 1014
Study: 28651368

Group type: EXPERIMENTAL
Intervention: Grade 1a PitNETs
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Grade 2b PitNETs
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Overall classification of PitNETs
Number of subjects: 365
Study: 28651559

Group type: EXPERIMENTAL
Intervention: Energy-intake weight balance method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doubly-labeled water (DLW) method
Number of subjects: 0
Study: 28651572

Group type: EXPERIMENTAL
Intervention: Seal-wing paclitaxel-eluting balloon catheters (PEB)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Iopromide-coated PEB
Number of subjects: 64

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 64
Study: 28651604

Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 286
Study: 28652227

Group type: EXPERIMENTAL
Intervention: Mobile app providing tailored information linked to electronic health records (EHR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile app features include viewing laboratory results, accessing educational material, and appointment scheduling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration with National Cancer Institute (NCI) databases and EHR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of EHR-based Web services for real-time data retrieval
Number of subjects: 0
Study: 28652228

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n=17) received education session, Fitbit Flex, and weekly telephone counselling.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Delayed intervention group (n=17) received the same intervention 1 month later.
Number of subjects: 34
Study: 28652960

Group type: EXPERIMENTAL
Intervention: Online obesity prevention program
Number of subjects: 342
Study: 28653250

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (initiated by 990 survivors with estrogen-receptor-positive cancers)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Self-reported cognitive function (measured using the EORTC-QLQ30 scale)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Cognitive problems
Number of subjects: 1280
Study: 28653440

Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRC) injected directly into the axillary region combined with a scar-releasing fat graft procedure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adipose-derived regenerative cells (ADRC)
Number of subjects: 10
Study: 28653498

Group type: EXPERIMENTAL
Intervention: MA-CORD intervention (WIC program changes)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intervention Site #2
Number of subjects: 198

Group type: COMPARATOR
Intervention: Comparison WIC program
Number of subjects: 198
Study: 28653502

Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in Community 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in Community 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MA-CORD intervention in both communities
Number of subjects: 0
Study: 28653504

Group type: EXPERIMENTAL
Intervention: Massachusetts Childhood Obesity Research Demonstration (MA-CORD) intervention at Intervention Site #2 (n=1,368)
Number of subjects: 3685

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) site (n=2,286)
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: Massachusetts Childhood Obesity Research Demonstration (MA-CORD) intervention at Intervention Site #1 (n=111)
Number of subjects: 3685
Study: 28653559

Group type: EXPERIMENTAL
Intervention: Written information (n = 13)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Counseling (n = 36)
Number of subjects: 49
Study: 28654207

Group type: EXPERIMENTAL
Intervention: Grape polyphenols (resveratrol, grape seed extract, grape juice; 2125 mg total polyphenols)
Number of subjects: 12
Study: 28654347

Group type: EXPERIMENTAL
Intervention: PulmoBind, a ligand of the adrenomedullin receptor, used for molecular imaging of pulmonary circulation.
Number of subjects: 0
Study: 28654574

Group type: EXPERIMENTAL
Intervention: Capecitabine 1000 mg/m² twice daily and Celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle
Number of subjects: 6
Study: 28655452

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg twice daily with prednisone (P) 5 mg twice daily after progression from standard-dose therapy.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard-dose therapy of Abiraterone acetate (AA) 1000 mg daily with prednisone (P) 5 mg twice daily.
Number of subjects: 41